Key Metrics 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Saamya Biotech (India) Ltd (532905)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 532905 NSE: Pharmaceuticals & Drugs | Small Cap | Saamya Biotech (I) Share Price
BSE Share Price
Not Listed
Not Listed
Saamya Biotech (India) Ltd (532905)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 532905 NSE: Pharmaceuticals & Drugs | Small Cap | Saamya Biotech (I) Share Price
BSE Share Price
Not Listed
Not Listed
Key Metrics
Valuation Multiples
Market Cap
₹5 Cr.
Current Price
₹0
52-Week Low / High
₹2 / 2
TTM EPS
-
TTM Sales
-
Book Value per Share
-
P/E Ratio
Industry PE
53.9
Price to Book (P/B)
Price to Sales (P/S)
EV/EBITDA
Dividend Yield
NAN%
Profitability Efficiency
Return on Equity (ROE)
%
Return on Capital Employed (ROCE)
%
Return on Assets (ROA)
%
Operating Profit Margin
0%
Net Profit Margin
-%
Gross Profit Margin
0%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Slowing versus 3-year growth rate
-49.95%
Operating Profit Growth (1 Year)
-
-
Net Profit Growth (1 Year)
-
-
Asset Quality
Promoter Holding
25.62%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
-
Equity
₹24.9 Cr.
Face Value
₹10
All Time Low / High
₹0.98 / 31.95
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Value Creation ⓘ
| Mar'07 | Mar'08 | Mar'09 | Mar'10 | Mar'11 | Mar'12 | Mar'13 | Mar'14 | Mar'15 | Mar'16 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 0% | 0% | 0% | 0.1% | 0.7% | 3.5% | -1.1% | 0.5% | -2.2% | -2.9% | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 0 | 0 | 0 | 2.4 | 16.3 | 23.1 | 3 | 13.4 | 28.8 | 14.4 | 0 |
| Sales YoY Gr. | - | NA | NA | NA | 592.8% | 41.7% | -87.1% | 348.3% | 115.3% | -50% | - |
| Adj EPS ⓘ | 0 | 0 | 0 | 0 | 0.1 | -0.1 | -0.2 | 0.1 | -0.3 | -0.2 | -0 |
| YoY Gr. | - | NA | NA | NA | 700% | -187.5% | NA | NA | -660% | NA | - |
| BVPS (₹) ⓘ | 10 | 10 | 10 | 10 | 10.1 | 11.9 | 11.8 | 11.8 | 11.5 | 11.4 | 11.3 |
| Adj Net Profit ⓘ | 0 | 0 | 0 | 0 | 0.2 | -0.2 | -0.4 | 0.1 | -0.7 | -0.5 | -0 |
| Cash Flow from Ops. ⓘ | -1 | -2.2 | -3.9 | 0.4 | -0.7 | -1 | -0.2 | -0.2 | 0.6 | 0.1 | - |
| Debt/CF from Ops. ⓘ | -0.6 | -0.5 | -0 | 0.4 | -0.3 | -0.4 | -1.8 | -20 | 5.8 | 39.5 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | NA | -2.4% | 69.1% | -50% | ||||
| Adj EPS ⓘ | NA | -221.3% | NA | NA | ||||
| BVPSⓘ | 1.5% | 2.5% | -1.2% | -1.6% | ||||
| Share Price | - | - | - | - | ||||
Key Financial Parameters ⓘ
| Mar'07 | Mar'08 | Mar'09 | Mar'10 | Mar'11 | Mar'12 | Mar'13 | Mar'14 | Mar'15 | Mar'16 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 0 | 0 | 0 | 0.1 | 0.6 | -0.5 | -1.1 | 0.4 | -2.4 | -1.8 | -0.1 |
| Op. Profit Mgn % ⓘ | 0 | 0 | 0 | 1.4 | 2.6 | 2.5 | -9.1 | 2.5 | 0.8 | -0.9 | NAN |
| Net Profit Mgn % ⓘ | 0 | 0 | 0 | 0.9 | 1.1 | -0.8 | -12.6 | 1 | -2.4 | -3.6 | -INF |
| Debt to Equity ⓘ | 0.1 | 0 | 0 | 0 | 0 | 0 | 0 | 0.2 | 0.1 | 0.1 | - |
| Working Cap Days ⓘ | 0 | 0 | 0 | 2,159 | 145 | 233 | 2,599 | 480 | 353 | 1,146 | 0 |
| Cash Conv. Cycle ⓘ | 0 | 0 | 0 | 1 | 3 | 13 | 322 | 42 | 32 | 99 | 0 |
Valuation of Saamya Biotech (I) - Consolidated
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Financials
No data found!
No data found!
No data found!
No data found!
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Saamya Biotech (India) Ltd FAQs
The current trading price of Saamya Biotech (I) on 01-Jan-1970 05:30 is ₹0.00.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Dec-1969 the market cap of Saamya Biotech (I) stood at ₹4.90 Cr
The latest P/E ratio of Saamya Biotech (I) as of 31-Dec-1969 is 0.00.
The latest P/B ratio of Saamya Biotech (I) as of 31-Dec-1969 is 0.17.
The 52-week high of Saamya Biotech (I) is ₹2.07 and the 52-week low is ₹1.97.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Saamya Biotech (I) is ₹0.00 ( Cr.) .
Data is not available for this company.
No data found
No data found
About Saamya Biotech (India) Ltd
Saamya Biotech (India) was incorporated as a public limited company on August 13, 2002 and certificate of commencement of business was issued on August 26, 2002. The promoters of the company are Dr. Y. Manivardhan Reddy and Dr. Y. Sonia Reddy and it is engaged in business of manufacturing, import, export and dealing in all types of chemicals pharmaceuticals drugs and intermediates.
Saamya Biotech (India) (SBIL) is a new generation biotechnology company incorporated in India (Hyderabad) with the aim to manufacture and market biopharmaceuticals and recombinant protein products of medical and industrial importance, and also to discover and develop emerging biotech products of far reaching significance. The company proposes to set up world class facilities for the manufacture of fermentation based high value biotech products. The company embarks on developing effective strategies for the production and supply of both bulk and formulations with special focus on life saving drug entities at affordable price.
The company has entered into technology transfer agreement with Biofin laboratories s.r.l Italy for technology know-how to manufacture bio-pharmaceutical ingredients.
The company entered into sales and purchase agreement with Finchimica, Italy on September 18, 2004, in terms of which Finchimica, Italy would buy all the products manufactured by it to the extent of 100%.
Product range off the company includes:
- Daunomycin
- Hyaluronic acid (Pharma grade)
- Tacrolimus and Rapamycin
- Cyclosporin A, Probiotics
- Lysergic acid
- Mycophenolic acid
- Clavulenic acid
- Vancomycin
- Co-enzyme Q10
- Interferon β
- Monoclonal antibodies (anti-cancer).
You have 49 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
